MarketVue® Report
Palmoplantar Pustulosis (PPP) (U.S.), 2022

Syndicated market assessment report driven by primary market research

REPORT STORE

Palmoplantar Pustulosis (PPP) (U.S.), January 2022

DOWNLOAD SAMPLE REPORT
DOWNLOAD REPORT BROCHURE
The MarketVue®: Palmoplantar Pustulosis market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
 
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
 
Topics covered in this report:
  • Disease overview: Review the disease pathophysiology and potential druggable targets
  • Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
  • Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
  • Unmet needs: Identify opportunities to address treatment or disease management gaps
  • Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
  • Value and access: Gain insights into the drug pricing landscape and payer controls within the disease market or analogous markets
 
Methodology:
Research for the MarketVue®: Palmoplantar Pustulosis report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 27 U.S. physicians and secondary research.
 
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
 
Key companies mentioned:
  • AnaptysBio
  • Boehringer Ingelheim
  • Novartis
  • Aristea Therapeutics
  • Janssen
  • Kyowa Kirin
  • AbbVie
  • Amgen
  • CSL Behring
  • Inmagene
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • KHK
  • Regeneron
  • Eli Lilly
  • Maruho
 
Key drugs mentioned:
  • Acitretin
  • Methotrexate
  • Cyclosporine
  • Etanercept (Enbrel)
  • Adalimumab (Humira)
  • Ixekizumab (Taltz)
  • Brodalumab (Siliq, Kyntheum, Lumicef)
  • Apremilast (Otezla)
  • Ustekinumab (Stelara)
  • Guselkumab (Tremfya)
  • Risankizumab (Skyrizi)
  • Imsidolimab
  • Spesolimab (Spevigo)
  • Secukinumab (Cosentyx)
  • RIST4721
  • CSL324
  • Anumigilimab
  • IMG-008
  • REGN 6490
  • Anakinra
  • LY3041658
  • Maxacalcitol
1. DISEASE OVERVIEW
A recurrent inflammatory disorder causing pustules on the hands and feet
Figure 1.1 – Conditions related to PPP
Disease pathogenesis
Figure 1.2. Autoimmune and autoinflammatory drivers of PPP disease pathogenesis
Figure 1.3 – Treatments effective in psoriasis are not effective in PPP
PPP is a distinguishable disease
Figure 1.4. Clinical and genetic differences between pustular psoriasis subtypes
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1 – G6 prevalent cases of PPP by region
Table 2.1 – Prevalent and drug-treated populations of PPP in the U.S. and EU5
3. CURRENT TREATMENT
Overview
Figure 3.1 – Treatment goals for PPP
Standard of care
Figure 3.2 – Current treatment patient share
TNF inhibitors and IL-17 inhibitors are the most commonly used biologics in PPP
Figure 3.3 – Dermatologist-reported biologic use in PPP patients by drug class
Figure 3.4. Percentage of PPP patients who proceed from first-line to a second-line biologic
Figure 3.5 – Dermatologist preferred second-line biologic
Dermatologists choose biologics that are effective in psoriasis
Treatment decisions for PPP
Figure 3.6 – Treatment algorithm for PPP
Dermatologists tend to categorize PPP as a form of psoriasis
Figure 3.7 – Dermatologists’ opinion on the relationship between PPP and psoriasis
Figure 3.8. Evolution of PPP as a distinct indication
Current PPP treatment options are minimally effective
Table 3.1 – Upside and downsides of currently off-label PPP treatments
Current treatment options have their limitations
Key treatment dynamics that shape disease management and drug use
Table 3.2 – Must-know PPP treatment dynamics for now and the future
Figure 3.9 – Percentage of PPP patients who are not achieving satisfactory outcomes with current treatments
PPP has a severe psychosocial and quality of life impact on patients
Figure 3.10 – Dermatologists’ rating of the impact of PPP on patients
First approved therapies for PPP likely to be label expansions
Figure 3.11 – Important dynamics of PPP market evolution
4. UNMET NEED
Overview
Top unmet needs in PPP
Figure 4.1 – Dermatologist-reported unmet needs in PPP
Physician perspectives on unmet needs in PPP
Figure 4.2 – U.S. dermatologists ranking of the need for new treatments in dermatology
5. PIPELINE ANALYSIS
Drug development for PPP
Figure 5.1 – Number of clinical stage therapies addressing unmet needs in PPP
Figure 5.2 – Percent of U.S. dermatologists rating PPP emerging therapy target as “promising”
Opinions are mixed on which MOA is the most promising
Summary of clinical-stage emerging PPP therapies
Table 5.1 – Emerging PPP therapies, Phase 1 to Phase 3
Competitor pipeline overview
Figure 5.3. – Current pipeline shows several therapies in varying stages of development
6. VALUE & ACCESS
Overview
Table 6.1 – Current therapy pricing, US 2021
Biologics require prior authorization on commercial insurance plans
Figure 6.1 – Reimbursement and Access considerations for emerging therapies in PPP
Medicare reimbursement stands to be a high barrier for patient access to novel PPP therapies
Regulatory considerations in PPP
Figure 6.2. – Key regulatory factors in PPP
7. METHODOLOGY
Primary market research approach
Epidemiology methodology
What is the difference between purchasing a published report and requesting a new report?

Published reports have been pre-produced on the specified date and can be delivered immediately. If you prefer to refresh an existing report or request an entirely new disease, REACH can create and deliver any new report within 15 business days.

How does REACH produce new primary market research reports in 15 business days?

By deploying our senior team to each of our reports, we can begin insight generation on day 1. The REACH team also recruits Key Opinion Leaders from our internal panel rather than outsourcing recruitment which enables us to quickly begin primary market research interviews.

Who writes REACH reports?

Each REACH report is produced by one of our senior US-based team members with 10+ years of experience in life sciences market research. We are deeply committed to ensuring REACH reports are high quality and strategic to enable informed decision-making for our clients.

Does REACH cover both rare and non-rare diseases?

REACH specializes in covering diseases and subpopulations that are not addressed by traditional market research reports. As such, we focus on rare diseases and niche subpopulations of more common conditions (e.g., Dupixent-refractory atopic dermatitis). Our flexible model enables in-depth assessments across all disease types, allowing us to support research for non-rare conditions as well.

Can I meet with the team to discuss the report?

Contact us to set up a call directly with the analyst who has written the report to answer any questions and discuss the key takeaways.

Published Report

Download immediately.


New Report

Updated upon purchase. Delivered in 15 days.


Undecided about purchasing this report?

» Inquire before buying

Reach out to learn more about report bundle discounts

Reach out to our team to learn more about our capabilities and view sample reports.

Contact us